UCB (UCB.BR) stock price, revenue, and financials

UCB market cap is €20.1 b, and annual revenue was €5.35 b in FY 2020

€20.1 B

UCB.BR Mkt cap, 10-Nov-2021

€5.3 B

UCB Revenue FY, 2020
UCB Revenue growth (FY, 2019 - FY, 2020), %9%
UCB Gross profit (FY, 2020)4 B
UCB Gross profit margin (FY, 2020), %74.5%
UCB Net income (FY, 2020)761 M
UCB EBITDA (FY, 2020)1.1 B
UCB EBIT (FY, 2020)971 M
UCB Cash, 31-Dec-20201.3 B
UCB EV21.5 B
Get notified regarding key financial metrics and revenue changes at UCBLearn more
Banner background

UCB Revenue

UCB revenue was €5.35 b in FY, 2020 which is a 8.8% year over year increase from the previous period.

Embed Graph

UCB Revenue Breakdown

Embed Graph

UCB revenue breakdown by business segment: 35.8% from Cimzia®, 28.9% from Vimpat®, 15.7% from Keppra®, 6.2% from Neupro®, 5.7% from Briviact® and 7.7% from Other

UCB revenue breakdown by geographic segment: 17.7% from International, 27.4% from Europe and 54.9% from U.S.

UCB Income Statement

Annual

EURFY, 2018FY, 2019FY, 2020

Revenue

4.6b4.9b5.3b

Revenue growth, %

6%9%

Cost of goods sold

1.2b1.3b1.4b

Gross profit

3.4b3.6b4.0b

Gross profit Margin, %

74%74%75%

Sales and marketing expense

964.0m1.1b1.2b

R&D expense

1.2b1.3b1.6b

General and administrative expense

180.0m195.0m196.0m

Operating expense total

2.3b2.6b3.0b

EBITDA

1.1b1.1b1.1b

EBITDA margin, %

24%23%20%

EBIT

1.1b1.1b971.0m

EBIT margin, %

24%22%18%

Interest expense

59.0m57.0m64.0m

Interest income

16.0m17.0m14.0m

Pre tax profit

1.0b960.0m880.0m

Income tax expense

200.0m146.0m119.0m

Net Income

823.0m817.0m761.0m

EPS

4.24.23.8

Half Year

EURH1, 2018H1, 2019H1, 2020

Revenue

2.3b2.3b2.6b

Cost of goods sold

573.0m598.0m683.0m

Gross profit

1.7b1.7b1.9b

Gross profit Margin, %

75%74%74%

Sales and marketing expense

422.0m502.0m569.0m

R&D expense

500.0m568.0m689.0m

General and administrative expense

88.0m96.0m94.0m

Operating expense total

1.0b1.2b1.4b

EBITDA

657.0m571.0m614.0m

EBITDA margin, %

29%25%24%

EBIT

676.0m598.0m519.0m

EBIT margin, %

30%26%20%

Pre tax profit

629.0m544.0m458.0m

Income tax expense

56.0m108.0m70.0m

Net Income

574.0m437.0m388.0m

EPS

2.92.21.9

UCB Balance Sheet

Annual

EURFY, 2018FY, 2019FY, 2020

Cash

1.3b1.3b1.3b

Accounts Receivable

625.0m700.0m742.0m

Prepaid Expenses

95.0m129.0m140.0m

Inventories

647.0m780.0m854.0m

Current Assets

3.0b3.3b3.6b

PP&E

805.0m840.0m1.0b

Goodwill

5.0b5.1b5.0b

Total Assets

10.5b11.1b13.3b

Accounts Payable

364.0m403.0m513.0m

Short-term debt

149.0m306.0m431.0m

Current Liabilities

2.2b2.4b2.8b

Long-term debt

1.4b975.0m2.3b

Non-Current Liabilities

2.0b1.7b3.2b

Total Debt

1.5b1.3b2.7b

Total Liabilities

4.3b4.1b6.0b

Common Stock

2.6b2.6b2.6b

Additional Paid-in Capital

(342.0m)(377.0m)(393.0m)

Retained Earnings

4.4b5.0b5.5b

Total Equity

6.3b7.0b7.3b

Debt to Equity Ratio

0.2 x0.2 x0.4 x

Debt to Assets Ratio

0.1 x0.1 x0.2 x

Financial Leverage

1.7 x1.6 x1.8 x

Half Year

EURH1, 2018H1, 2019H1, 2020

Cash

895.0m1.0b968.0m

Inventories

632.0m706.0m825.0m

Current Assets

2.6b2.8b3.1b

PP&E

795.0m828.0m881.0m

Goodwill

4.9b5.0b5.3b

Total Assets

10.2b10.5b13.2b

Short-term debt

219.0m386.0m419.0m

Current Liabilities

2.1b2.4b2.6b

Long-term debt

1.4b1.0b2.5b

Non-Current Liabilities

2.2b1.7b3.6b

Total Debt

1.7b1.4b2.9b

Total Liabilities

4.3b4.1b6.1b

Common Stock

2.6b2.6b2.6b

Additional Paid-in Capital

(373.0m)(384.0m)(374.0m)

Retained Earnings

4.1b4.6b5.1b

Total Equity

5.9b6.5b7.1b

Debt to Equity Ratio

0.3 x0.2 x0.4 x

Debt to Assets Ratio

0.2 x0.1 x0.2 x

Financial Leverage

1.7 x1.6 x1.9 x

UCB Cash Flow

Annual

EURFY, 2018FY, 2019FY, 2020

Net Income

823.0m817.0m761.0m

Depreciation and Amortization

288.0m313.0m354.0m

Accounts Receivable

(32.0m)(147.0m)(105.0m)

Inventories

(53.0m)(134.0m)(74.0m)

Accounts Payable

69.0m60.0m258.0m

Cash From Operating Activities

1.1b882.0m1.1b

Purchases of PP&E

(94.0m)(99.0m)(256.0m)

Cash From Investing Activities

(320.0m)(235.0m)(2.2b)

Long-term Borrowings

(210.0m)(166.0m)(457.0m)

Dividends Paid

(222.0m)(228.0m)(235.0m)

Cash From Financing Activities

(538.0m)(605.0m)1.2b

Net Change in Cash

231.0m42.0m30.0m

Interest Paid

63.0m59.0m70.0m

Income Taxes Paid

168.0m89.0m72.0m

Half Year

EURH1, 2018H1, 2019H1, 2020

Net Income

574.0m437.0m388.0m

Depreciation and Amortization

139.0m151.0m172.0m

Accounts Receivable

(49.0m)(101.0m)(149.0m)

Inventories

(35.0m)(59.0m)(45.0m)

Accounts Payable

(42.0m)(69.0m)106.0m

Cash From Operating Activities

490.0m351.0m377.0m

Purchases of PP&E

(49.0m)(47.0m)(66.0m)

Cash From Investing Activities

(283.0m)(129.0m)(1.9b)

Long-term Borrowings

(38.0m)(132.0m)(289.0m)

Dividends Paid

(222.0m)(228.0m)(235.0m)

Cash From Financing Activities

(345.0m)(477.0m)1.3b

Net Change in Cash

(138.0m)(255.0m)(316.0m)

Interest Paid

42.0m40.0m(40.0m)

Income Taxes Paid

107.0m40.0m35.0m

UCB Ratios

EURH1, 2018

Debt/Equity

0.3 x

Debt/Assets

0.2 x

Financial Leverage

1.7 x

UCB Operating Metrics

FY, 2018H1, 2019FY, 2019H1, 2020FY, 2020

Patients Reached

3.3 m3.34 m3.5 m3.4 m3.5 m

Projects in Pipeline

10712

Countries

35

Locations (Research and Development)

12

UCB Employee Rating

4.1642 votes
Culture & Values
3.8
Work/Life Balance
3.7
Senior Management
3.2
Salary & Benefits
3.7
Career Opportunities
3.3
Source